GRI Bio

GRI

Market cap $4.55M

Overview Fund Activity

1.81 USD

-0.24

11.71%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

1.80

-0.01

0.55%

1 day

-11.71%

5 days

9.7%

1 month

42.52%

3 months

29.29%

6 months

-69.58%

Year to date

-87.47%

1 year

-78.9%

5 years

-100%

10 years

-100%

About: GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Employees: 4

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

63% more capital invested

Capital invested by funds: $15.5K [Q1] → $25.3K (+$9.81K) [Q2]

0% more funds holding

Funds holding: 5 [Q1] → 5 (+0) [Q2]

0% more ownership

Funds ownership: 0.92% [Q1] → 0.92% (+0%) [Q2]

See Fund Rankings

Financial journalist opinion

GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

No decline in lung function observed at 6-week interim analysis builds upon positive safety and biomarker data

GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Live video webcast on Wednesday, August 20 th at 2:20 PM ET LA JOLLA, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details for the presentation are as follows: Date and Time: Wednesday, August 20, 2025 at 2:20 PM ET Presenter: Marc Hertz, PhD, President, Chief Executive Officer and Director Registration Link: HERE About Webull Financial Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology.

GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment

Access the “What This Means” segment here

GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment

GRI Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

– Video webcast now available on-demand LA JOLLA, CA, July 22, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced Marc Hertz, PhD, President, Chief Executive Officer and Director of GRI BIO, participated in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference. As part of the event, Dr. Hertz dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company's programs in development.

GRI Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival

GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

The Independent Data Monitoring Committee (“IDMC”) has recommended to continue the study as planned as there are no safety concerns demonstrated in the data reviewed

GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio to Participate in the Virtual Investor Closing Bell Series

Live webcast on Wednesday, May 28 th at 4:00 PM ET LA JOLLA, CA, May 21, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio will participate in the Virtual Investor Closing Bell Series on Wednesday, May 28, 2025 at 4:00 PM ET. As part of the event, Dr. Hertz will provide a corporate overview and business outlook.

GRI Bio to Participate in the Virtual Investor Closing Bell Series

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer on Wednesday, May 21 st at 2:40 PM ET

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

Positive interim 2-week safety and biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

The Independent Data Monitoring Committee (IDMC) has recommended to continue the study as planned as there are no safety concerns seen in the data reviewed

GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

See News Rankings

Charts implemented using Lightweight Charts™